Bradycardia-induced heart failure with preserved ejection fraction successfully treated with empagliflozin and theophylline: a case report.
心動過緩引起的保留射血分數心衰竭成功治療案例:使用 empagliflozin 和 theophylline。
Eur Heart J Case Rep 2024-09-17
Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible.
心衰竭伴隨保留射血分數的 empagliflozin:在不可能任務中的首次成功。
Eur Heart J Suppl 2022-11-17
Effect of SGLT2 inhibitor empagliflozin on the stabilization of heart failure progress with the possibility of further interventions in a patient with HFrEF - a case report.
SGLT2 抑制劑 empagliflozin 對 HFrEF 患者心衰進展穩定及進一步干預可能性的影響 - 一個病例報告。
Vnitr Lek 2022-11-22
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
心臟衰竭伴隨保留射血分數的心房顫動中的 Empagliflozin。
Eur J Heart Fail 2023-08-09
Effect of sodium-glucose co-transporter-2 inhibitor empagliflozin on disease progression in a patient with heart failure and preserved ejection fraction.
SGLT-2 抑制劑 empagliflozin 對心臟衰竭患者保留射血分數疾病進展的影響。
Vnitr Lek 2023-07-21
Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
Empagliflozin 抑制 HFpEF 患者心房心肌細胞中增加的鈉流入。
Cardiovasc Res 2024-05-10
Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain.
Empagliflozin 通過重新穩定線粒體呼吸鏈,改善 HFpEF 的舒張功能。
Circ Heart Fail 2024-06-07